A Breakthrough in Heart Health
Heart health is everything. PCSK9 inhibitors are changing the way we manage cholesterol – helping people take control of their future with confidence.
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a protein that is mostly produced by the liver, and less so by the intestine and other organs. The liver controls LDL (“bad”) cholesterol levels using special LDL receptors that help remove it from the blood. PCSK9 is a protein that breaks down these receptors. When there are fewer receptors, more LDL cholesterol stays in the bloodstream. However, blocking PCSK9 allows more LDL receptors to remain, helping the liver clear more LDL and lowering cholesterol levels.
Inclisiran a next-generation treatment, is a small interfering RNA, which Blocks PCSK9 production, giving your liver a better chance to remove LDL. The result? A significant drop in cholesterol and a reduced risk of heart disease.
Who Should Consider PCSK9 Inhibitors?
Inclisiran is recommended for people with primary hypercholesterolaemia or mixed dyslipidaemia and is licensed for use in the UK under specific conditions set by NICE. It may be an option if:
✔ You have a history of cardiovascular events, such as a heart attack, stroke, or peripheral arterial disease.
✔ Your LDL cholesterol is 2.6 mmol/L or higher, despite taking the maximum tolerated dose of lipid-lowering therapy.
✔ Statins don’t work well enough for you—or cause side effects.
✔ You have other cardiovascular risk factors, such as high blood pressure, obesity, or a strong family history of heart disease.
Even if you haven’t had a heart attack or stroke, reducing LDL cholesterol can be a key step in prevention.
The Benefits
– Reduces LDL cholesterol by 50-60%, lowering heart attack risk by nearly 25%.
– Potential longevity benefits, with ongoing research exploring long-term effects.
– Easy and convenient—after the first dose, one injection at 3 months, then just every 6 months.
– Missed a dose? If more than 3 months late, treatment should be restarted.
Safety and Risks
Inclisiran was approved in 2021 after extensive research and has been proven safe for over six years. The most common side effect? Mild, temporary redness or swelling at the injection site. Currently there is very little evidence for use in Pregnancy or whilst breast feeding, so it is recommended to avoid during these periods.
A Smarter, Simpler Way to Protect Your Heart
Inclisiran offers a powerful and convenient way to take charge of your heart health. If you’re looking for an effective, well-tolerated solution to lower cholesterol and reduce risk, PCSK9 inhibitors could be the answer.
